Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
Status:
Completed
Trial end date:
2017-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated
Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given
with a targeted agent, bevacizumab, and how effective this study treatment will be in
controlling your brain tumor.